Literature DB >> 672141

Hypercalcitoninaemia in patients with pheochromocytoma.

F Raue, J M Bayer, K H Rahn, C Herfarth, H Minne, R Ziegler.   

Abstract

As pheochromocytoma sometimes is accompanied by medullary thyroid carcinoma (in the sense of multiple endocrine adonomatosis type II = Sipple-Syndrome), serum calcitonin (CT) was measured by radioimmunoassay in 4 patients with pheochromocytoma. Before extirpation of the adreno-medullary tumor, serum CT was distinctly increased to 3 and 30 ng/ml in 2 of 4 patients, respectively. After removal of the tumor, serum CT was normal in the patients and pentagastrin stimulation produced no exaggerated CT response. In hydrochloric acid extracts from the two corresponding pheochromocytoma tissues, immunoreactive-Calcitonin (IR-CT) was detected, the concentrations amounting 1 and 4 ng/mg wet tissue. These findings suggest that hypercalcitonism in patients with pheochromocytoma cannot always be ascribed to the thyroid, i.e. increased calcitonin levels do not necessarily indicate a medullary carcinoma of this organ.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 672141     DOI: 10.1007/BF02429104

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  Adrenal medullary calcitonin-like factor: a key to multiple endocrine neoplasia, type 2?

Authors:  E L Kaplan; C D Arnaud; B J Hill; G W Peskin
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

2.  Stimulation tests for diagnosis of medullary thyroid carcinoma.

Authors:  G W Sizemore; V L Go
Journal:  Mayo Clin Proc       Date:  1975-02       Impact factor: 7.616

3.  The ultimobranchial origin of calcitonin.

Authors:  J M Moseley; E W Matthews; R H Breed; L Galante; A Tse; I MacIntyre
Journal:  Lancet       Date:  1968-01-20       Impact factor: 79.321

4.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

5.  Letter: Hypersecretion of calcitonin in neoplastic conditions.

Authors:  G Milhaud; C Calmette; J Taboulet; A Julienne; M S Moukhtar
Journal:  Lancet       Date:  1974-03-16       Impact factor: 79.321

6.  Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours.

Authors:  R C Coombes; C Hillyard; P B Greenberg; I MacIntyre
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

7.  Letter: Plasma-calcitonin and non-thyroid tumours.

Authors:  B Greenfield
Journal:  Lancet       Date:  1974-07-20       Impact factor: 79.321

8.  Familial medullary carcinoma of the thyroid, adrenal pheochromocytoma and parathyroid hyperplasia. A syndrome of multiple endocrine neoplasia.

Authors:  K D Pearson; S A Wells; H R Keiser
Journal:  Radiology       Date:  1973-05       Impact factor: 11.105

9.  [The determination of calcitonin for hospital use (author's transl)].

Authors:  F Raue; H Minne; D Schäfer; R Ziegler
Journal:  MMW Munch Med Wochenschr       Date:  1977-02-18

10.  Immunoassay for human calcitonin. II. Clinical studies.

Authors:  L J Deftos; A E Bury; J F Habener; F R Singer; J T Potts
Journal:  Metabolism       Date:  1971-12       Impact factor: 8.694

View more
  3 in total

1.  Immunohistochemical study of pheochromocytomas. An investigation of methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin in 16 tumors.

Authors:  J Hassoun; G Monges; P Giraud; J F Henry; C Charpin; H Payan; M Toga
Journal:  Am J Pathol       Date:  1984-01       Impact factor: 4.307

2.  The importance of multiple endocrine neoplasia syndromes in differential diagnosis.

Authors:  L Schaaf; M Greschner; W Geissler; B Eckert; F J Seif; K H Usadel
Journal:  Klin Wochenschr       Date:  1990-07-05

3.  Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B).

Authors:  K Frank; F Raue; J Gottswinter; U Heinrich; H Meybier; R Ziegler
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.